Novo Nordisk (NVO) has redrawn the battle lines in the obesity market with an oral pill that is already rewriting launch records. Its oral formulation of Wegovy, introduced in the U.S. in January, had racked up more than three million prescriptions by June — one of the strongest starts by volume for any pharmaceutical product in U.S. history. More notably, over 80% of those new prescriptions came from patients who had never used a GLP-1 medicine, signaling that the pill is expanding the market rather than merely siphoning patients from injectables.
Within the narrow but fast-growing oral weight-loss category, Novo Nordisk now holds a commanding lead. Some estimates put oral Wegovy’s share of U.S. oral anti-obesity prescriptions at around 89%, leaving Eli Lilly (LLY)’s rival pill Foundayo, approved in April, far behind.
Three factors explain the lopsided momentum. First, the Wegovy brand has become deeply embedded in the weight-loss conversation, steering patients who want a convenient pill toward a name they already trust. Second, semaglutide, the active ingredient, has been on the market for years, giving physicians a deep reservoir of real-world prescribing experience. Third, while there have been no head-to-head studies, oral Wegovy posted stronger efficacy data in pivotal Phase 3 trials — a difference that carries weight in prescribing decisions even without a direct comparison.
Lilly is hardly defenseless. Foundayo can be taken at any time of day without food or water restrictions, whereas oral Wegovy must be taken first thing in the morning on an empty stomach. The Lilly pill is also chasing a broad set of label expansions: it has already completed Phase 3 studies in type 2 diabetes and is undergoing trials in obstructive sleep apnea, hypertension, osteoarthritis pain, and peripheral artery disease. Given that a significant portion of overweight and obese patients live with one or more of these comorbidities, new indications could meaningfully widen the eligible population. On pricing, Lilly has drawn a sharp line, setting self-pay at $149 per month for the lowest dose, aiming squarely at injection-averse and cost-sensitive patients.
Zoom out, however, and the trillion-dollar question for Lilly depends less on an immediate oral comeback and more on the pair of injectable drugs that already carry the company. In the first quarter of 2026, Mounjaro and Zepbound generated a combined $12.8 billion in revenue — nearly two-thirds of Lilly’s $19.8 billion total for the period. Mounjaro sales soared 125% year over year to $8.7 billion; Zepbound grew 80% to $4.2 billion. Volume surged 65%, easily absorbing a 13% decline in realized prices and driving overall revenue growth of 56%. Emboldened by the momentum, management lifted its full-year revenue forecast to a range of $82 billion to $85 billion, implying roughly 28% growth at the midpoint.
Lilly now commands a market capitalization of about $1.06 trillion, trading at roughly 33 times the midpoint of its adjusted earnings guidance. That premium rests on extraordinary growth and a pipeline that includes retatrutide, whose recent Phase 3 results have been compared to outcomes typically seen with bariatric surgery.
Yet the risks are as sharp as they are simple. Nearly two-thirds of revenue rides on a single molecule, and realized prices are falling. In the oral arena, Novo Nordisk’s 89% market share and its ability to attract a fresh wave of patients underscore that it remains Lilly’s most dangerous rival. Whether Lilly can keep compensating for price erosion with volume gains — and lean on its pipeline to ease the concentration risk — will determine whether its trillion-dollar market cap stands on solid ground.
